BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/15/2021 10:19:10 AM | Browse: 432 | Download: 676
 |
Received |
|
2020-12-17 23:19 |
|
Peer-Review Started |
|
2020-12-17 23:20 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-30 04:39 |
|
Revised |
|
2021-05-16 02:50 |
|
Second Decision |
|
2021-06-28 12:26 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-06-28 12:52 |
|
Articles in Press |
|
2021-06-28 12:52 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-07-12 10:41 |
|
Publish the Manuscript Online |
|
2021-07-15 10:19 |
| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Minireviews |
| Article Title |
Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia: A controversial but promising approach
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Alfredo Bellon and Kieuhanh Nguyen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Alfredo Bellon, MD, PhD, Assistant Professor, Department of Psychiatry and Behavioral Health, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, United States. alfredobellon@yahoo.com |
| Key Words |
Antidepressants; Metabolic syndrome; Cholesterol; Psychotic disorders; Antipsychotics; Body weight |
| Core Tip |
We searched MEDLINE and Google Scholar to find articles related to the cardiovascular effects of selective serotonin reuptake inhibitors (SSRIs) in patients with schizophrenia (SCZ) who are taking antipsychotics. We found evidence showing that fluvoxamine reduces metabolic factors in patients taking clozapine, but we also found that SSRIs as a group cause significant yet small increments in metabolic factors. There is also evidence that the effect of SSRIs on metabolic factors depends on which antipsychotics the patient is concurrently taking. Further research in this area is needed before any firm conclusion can be reached on whether SSRIs are beneficial or harmful for cardiovascular risk in SCZ. |
| Publish Date |
2021-07-15 10:19 |
| Citation |
Bellon A, Nguyen K. Selective serotonin reuptake inhibitors and risk reduction for cardiovascular disease in patients with schizophrenia; A controversial but promising approach. World J Psychiatr 2021; 11(7): 316-324 |
| URL |
https://www.wjgnet.com/2220-3206/full/v11/i7/316.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v11.i7.316 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
